Cyclo Therapeutics, Inc.

NasdaqCM:CYTH Lagerbericht

Marktkapitalisierung: US$20.7m

Cyclo Therapeutics Management

Management Kriterienprüfungen 4/4

Cyclo Therapeutics' CEO is N. Fine, appointed in Sep 2015, has a tenure of 9.17 years. total yearly compensation is $672.89K, comprised of 80.4% salary and 19.6% bonuses, including company stock and options. directly owns 2.59% of the company’s shares, worth $536.73K. The average tenure of the management team and the board of directors is 7.3 years and 10 years respectively.

Wichtige Informationen

N. Fine

Geschäftsführender

US$672.9k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts80.4%
Amtszeit als Geschäftsführer9.2yrs
Eigentum des Geschäftsführers2.6%
Durchschnittliche Amtszeit des Managements7.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder10yrs

Jüngste Management Updates

Recent updates

Cyclo Therapeutics GAAP EPS of -$0.41 beats by $0.12, revenue of $0.54M misses by $0.08M

Aug 16

Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation

Jul 12
Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation

We're A Little Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Jan 20
We're A Little Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Cyclo Therapeutics: Addressing The Fundamentals Of Alzheimer's Disease

Nov 16

Will Cyclo Therapeutics (NASDAQ:CYTH) Spend Its Cash Wisely?

Sep 28
Will Cyclo Therapeutics (NASDAQ:CYTH) Spend Its Cash Wisely?

Cyclo therapeutics to join Russell 2000 Index

Jun 14

We're Keeping An Eye On Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Jun 12
We're Keeping An Eye On Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Cyclo Therapeutics posts design protocol of pivotal late-stage study of Trappsol Cyclo

Apr 27

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von N. Fine im Vergleich zu den Einnahmen von Cyclo Therapeutics verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Jun 30 2024n/an/a

-US$21m

Mar 31 2024n/an/a

-US$19m

Dec 31 2023US$673kUS$541k

-US$20m

Sep 30 2023n/an/a

-US$19m

Jun 30 2023n/an/a

-US$19m

Mar 31 2023n/an/a

-US$18m

Dec 31 2022US$1mUS$541k

-US$15m

Sep 30 2022n/an/a

-US$13m

Jun 30 2022n/an/a

-US$13m

Mar 31 2022n/an/a

-US$13m

Dec 31 2021US$1mUS$508k

-US$14m

Sep 30 2021n/an/a

-US$14m

Jun 30 2021n/an/a

-US$12m

Mar 31 2021n/an/a

-US$10m

Dec 31 2020US$489kUS$400k

-US$9m

Sep 30 2020n/an/a

-US$9m

Jun 30 2020n/an/a

-US$9m

Mar 31 2020n/an/a

-US$8m

Dec 31 2019US$490kUS$400k

-US$8m

Sep 30 2019n/an/a

-US$6m

Jun 30 2019n/an/a

-US$5m

Mar 31 2019n/an/a

-US$5m

Dec 31 2018US$467kUS$400k

-US$4m

Sep 30 2018n/an/a

-US$4m

Jun 30 2018n/an/a

-US$4m

Mar 31 2018n/an/a

-US$4m

Dec 31 2017US$441kUS$400k

-US$4m

Vergütung im Vergleich zum Markt: N.'s total compensation ($USD672.89K) is about average for companies of similar size in the US market ($USD655.65K).

Entschädigung vs. Einkommen: N.'s compensation has been consistent with company performance over the past year.

Geschäftsführer

N. Fine (67 yo)

9.2yrs

Amtszeit

US$672,888

Vergütung

Mr. N. Scott Fine has been Chief Executive Officer of Cyclo Therapeutics, Inc. (formerly known as CTD Holdings, Inc.) since September 14, 2015. Mr. Fine served as the Chairman of Cyclo Therapeutics, Inc. s...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
N. Fine
CEO & Director9.2yrsUS$672.89k2.59%
$ 536.7k
C. Strattan
Founder & Directorno dataUS$33.00k1.06%
$ 220.4k
Joshua Fine
CFO & Secretary10.8yrsUS$463.98k0.059%
$ 12.2k
Michael Lisjak
Senior VP of Business Development & Chief Regulatory Officer5.3yrsUS$473.21k0.043%
$ 8.9k
Jeffrey Tate
COO, Chief Quality Officer & Director9.2yrsUS$255.14k0.32%
$ 66.4k
Lori McKenna
Global Head of Patient Advocacy3.5yrskeine Datenkeine Daten
Karen Mullen
Interim Chief Medical Officer1.8yrskeine Datenkeine Daten

7.3yrs

Durchschnittliche Betriebszugehörigkeit

66yo

Durchschnittliches Alter

Erfahrenes Management: CYTH's management team is seasoned and experienced (7.3 years average tenure).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
N. Fine
CEO & Director10.8yrsUS$672.89k2.59%
$ 536.7k
C. Strattan
Founder & Director34.8yrsUS$33.00k1.06%
$ 220.4k
Jeffrey Tate
COO, Chief Quality Officer & Director14.3yrsUS$255.14k0.32%
$ 66.4k
William Shanahan
Independent Director8.4yrsUS$40.13k0.47%
$ 96.5k
Markus Sieger
Independent Chairman10.8yrsUS$66.38k1.21%
$ 250.5k
Rita Colwell
Co-Chair of Scientific Advisory Boardno datakeine Datenkeine Daten
Sharon Hrynkow
Co-Chairman of Scientific Advisory Board10yrsUS$600.09kkeine Daten
F. Ostronic
Independent Vice Chairman10.6yrsUS$41.25k1.22%
$ 251.7k
Caroline Hastings
Member of Scientific Advisory Board9.7yrskeine Datenkeine Daten
Benny Liu
Member of Scientific Advisory Board9.5yrskeine Datenkeine Daten
Gerald F. Cox
Member of Scientific Advisory Board3.2yrskeine Datenkeine Daten
Randall Toig
Independent Director6.7yrsUS$35.63k0.44%
$ 90.7k

10.0yrs

Durchschnittliche Betriebszugehörigkeit

67yo

Durchschnittliches Alter

Erfahrener Vorstand: CYTH's board of directors are seasoned and experienced ( 10 years average tenure).